Atea Pharmaceuticals Issues Statement Regarding Director Nominations
Atea Pharmaceuticals (NASDAQ: AVIR), a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics, has received a notice from shareholder Bradley L. Radoff regarding his intention to nominate three director candidates for election to the Company's Board of Directors at the 2025 Annual Meeting of Stockholders.
The Company's Nominating and Corporate Governance Committee will evaluate the director candidates according to established practices. Atea's Board will provide its formal recommendation on director nominations in the upcoming definitive proxy statement and WHITE proxy card, to be filed with the SEC. The Company has emphasized that no shareholder action is required at this time, as the 2025 Annual Meeting has not yet been scheduled.
Atea has retained Evercore as financial advisor and Latham & Watkins LLP as legal counsel for this matter.
Atea Pharmaceuticals (NASDAQ: AVIR), una società biofarmaceutica in fase clinica focalizzata su terapie antivirali orali, ha ricevuto una comunicazione dall'azionista Bradley L. Radoff riguardante la sua intenzione di nominare tre candidati per il consiglio di amministrazione dell'azienda in occasione dell'Assemblea Annuale degli Azionisti del 2025.
Il Comitato di Nomina e Governance Aziendale valuterà i candidati secondo le pratiche stabilite. Il Consiglio di Atea fornirà la propria raccomandazione formale sulle nomine dei direttori nella prossima dichiarazione proxy definitiva e nella scheda proxy BIANCA, che sarà depositata presso la SEC. L'azienda ha sottolineato che al momento non è necessaria alcuna azione da parte degli azionisti, poiché l'Assemblea Annuale del 2025 non è ancora stata programmata.
Atea ha scelto Evercore come consulente finanziario e Latham & Watkins LLP come consulente legale per questa questione.
Atea Pharmaceuticals (NASDAQ: AVIR), una empresa biofarmacéutica en etapa clínica centrada en terapias antivirales orales, ha recibido un aviso del accionista Bradley L. Radoff sobre su intención de nominar a tres candidatos a director para la elección de la Junta Directiva de la compañía en la Reunión Anual de Accionistas de 2025.
El Comité de Nominaciones y Gobernanza Corporativa de la compañía evaluará a los candidatos a director de acuerdo con las prácticas establecidas. La Junta de Atea proporcionará su recomendación formal sobre las nominaciones de los directores en la próxima declaración de poder definitiva y en la tarjeta de poder BLANCA, que será presentada ante la SEC. La compañía ha enfatizado que no se requiere ninguna acción por parte de los accionistas en este momento, ya que la Reunión Anual de 2025 aún no se ha programado.
Atea ha contratado a Evercore como asesor financiero y a Latham & Watkins LLP como asesor legal para este asunto.
Atea Pharmaceuticals (NASDAQ: AVIR)는 경구 항바이러스 치료제에 초점을 맞춘 임상 단계의 생명공학 회사로, 주주인 브래들리 L. 라도프(Bradley L. Radoff)로부터 2025년 주주 총회에서 회사 이사회에 선출할 이사 후보 3명을 지명하겠다는 의사를 통보받았습니다.
회사의 지명 및 기업 거버넌스 위원회는 정해진 관행에 따라 이사 후보를 평가할 것입니다. Atea의 이사회는 SEC에 제출될 예정인 다음의 최종 위임장 및 백색 위임장에 대한 이사 지명에 대한 공식 권고를 제공할 것입니다. 회사는 2025년 주주 총회가 아직 계획되지 않았으므로 현재 주주 행동이 필요하지 않다고 강조했습니다.
Atea는 이 문제에 대해 Evercore를 재무 자문사로, Latham & Watkins LLP를 법률 자문사로 고용했습니다.
Atea Pharmaceuticals (NASDAQ: AVIR), une entreprise biopharmaceutique en phase clinique axée sur les thérapies antivirales orales, a reçu un avis de l'actionnaire Bradley L. Radoff concernant son intention de nommer trois candidats au conseil d'administration de la société lors de l'Assemblée Générale Annuelle des Actionnaires de 2025.
Le Comité de Nomination et de Gouvernance d'Entreprise de la société évaluera les candidats au conseil d'administration selon les pratiques établies. Le Conseil d'Atea fournira sa recommandation formelle sur les nominations des administrateurs dans la prochaine déclaration de procuration définitive et la carte de procuration BLANCHE, qui sera déposée auprès de la SEC. L'entreprise a souligné qu'aucune action des actionnaires n'est requise pour le moment, car l'Assemblée Générale Annuelle de 2025 n'a pas encore été programmée.
Atea a retenu Evercore comme conseiller financier et Latham & Watkins LLP comme conseiller juridique pour cette affaire.
Atea Pharmaceuticals (NASDAQ: AVIR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf orale antivirale Therapeutika konzentriert, hat eine Mitteilung von Aktionär Bradley L. Radoff erhalten, in der er seine Absicht erklärt, drei Kandidaten für die Wahl in den Vorstand des Unternehmens bei der Jahreshauptversammlung der Aktionäre 2025 zu nominieren.
Der Nominierungs- und Corporate Governance-Ausschuss des Unternehmens wird die Kandidaten gemäß den festgelegten Praktiken bewerten. Der Vorstand von Atea wird seine formelle Empfehlung zu den Vorstandsnominierungen in der bevorstehenden endgültigen Proxy-Erklärung und der WEISSEN Proxy-Karte abgeben, die bei der SEC eingereicht werden soll. Das Unternehmen hat betont, dass zu diesem Zeitpunkt keine Aktion der Aktionäre erforderlich ist, da die Jahreshauptversammlung 2025 noch nicht angesetzt wurde.
Atea hat Evercore als Finanzberater und Latham & Watkins LLP als rechtlichen Berater für diese Angelegenheit beauftragt.
- None.
- None.
No Shareholder Action is Required at this Time
BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today confirmed receipt of a notice from Bradley L. Radoff that he intends to nominate three director candidates to stand for election to the Atea Board of Directors at the Company’s 2025 Annual Meeting of Stockholders.
The Atea Board of Directors and management team engage in regular communications with Atea’s shareholders and regularly evaluate the Company’s strategy to enhance shareholder value. The Nominating and Corporate Governance Committee of the Atea Board of Directors will evaluate the director candidates consistent with its established practices. The Board will make its formal recommendation regarding director nominations in the Company’s definitive proxy statement and accompanying WHITE proxy card, which will be filed with the Securities and Exchange Commission ahead of Atea’s 2025 Annual Meeting of Stockholders. The 2025 Annual Meeting has not yet been scheduled, and Atea stockholders are not required to take any action at this time.
Evercore is serving as Atea’s financial advisor and Latham & Watkins LLP is serving as legal counsel.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Our lead program and current focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to statements regarding the Shareholder Group’s director nominees, the Company’s formal recommendation with respect to director nominations and the Company’s strategy to enhance shareholder value. When used herein, words including “expected,” “should,” “anticipated,” “believe.” “will,” “plans”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Atea’s current expectations and various assumptions. Atea believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Atea may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, uncertainties inherent in the drug discovery and development process and the regulatory submission or approval process, unexpected or unfavorable safety or efficacy data or results observed during clinical trials or in data readouts; delays in or disruptions to clinical trials or our business; our reliance on third parties over which we may not always have full control, our ability to manufacture sufficient commercial product, competition from approved treatments for HCV, as well as the other important factors discussed under the caption “Risk Factors” in Atea’s Annual Report on Form 10-K for the year ended December 31, 2024 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Atea may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing Atea’s views as of any date subsequent to the date of this press release.
Additional Information and Where to Find It
Atea intends to file with the SEC a definitive proxy statement on Schedule 14A, containing a form of WHITE proxy card, with respect to its solicitation of proxies for the 2025 Annual Meeting of Stockholders.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY ATEA AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION.
Investors and security holders may obtain copies of these documents and other documents filed with the SEC by Atea free of charge through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Atea are also available free of charge by accessing Atea’s website at www.ateapharma.com.
Participants in the Solicitation
Atea, its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies with respect to a solicitation by Atea. Information about Atea’s executive officers and directors is available in Atea’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 6, 2025 and in Atea’s definitive proxy statement on Schedule 14A for its 2024 Annual Meeting of Stockholders, which was filed with the SEC on April 26, 2024. To the extent holdings by our directors and executive officers of Atea securities reported in the definitive proxy statement for the 2024 Annual Meeting of Stockholders have changed, such changes have been or will be reflected on Statements of Change in Ownership on Forms 3, 4 or 5 filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov. Copies of the documents filed by Atea are also available free of charge by accessing Atea’s website at www.ateapharma.com.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
FAQ
What is the purpose of Bradley L. Radoff's nominations to Atea Pharmaceuticals (AVIR) board?
When will AVIR shareholders vote on the proposed director nominations?
What actions are required from AVIR shareholders regarding the director nominations?
Who are the advisors assisting Atea Pharmaceuticals (AVIR) with the director nominations?
